In the long human story of hope outpacing evidence, a peptide called 'Wolverine' has found its moment — spreading through American health markets without clinical trials, regulatory approval, or completed safety studies. Its rise is not accidental: when a sitting Health Secretary lends his voice to an unproven compound, institutional weight fills the space where scientific consensus has not yet formed. The episode raises a question as old as medicine itself — who guards the guardians when enthusiasm becomes policy?
Untested 'Wolverine' peptide gains traction despite lack of clinical validation
Science & Space